Interestingly, our approach to disrupt PD-1 expression on human T cells was successfully utilized on several cancer patients and healthy donors as the requirement of T cell editing for adoptive transfer of patient’s autologous lymphocytes or in some cases allogenetic lymphocytes of healthy donors. This evidence concerns the gene PDCD1 and cancer.